^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FASN-L

i
Entrez ID:
Related biomarkers:
22d
Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells. (PubMed, Anticancer Res)
Imipramine shows promise in enhancing HCC treatment outcomes in patients and targets the EGFR/MEK/ERK signaling pathway in in vitro HCC models, thereby augmenting the effectiveness of standard therapies.
Journal
|
ANXA5 (Annexin A5)
|
FASN-L
|
imipramine
2ms
Proteomics-based network pharmacology and molecular docking reveal the potential mechanisms of 5,6,7,4'-tetramethoxyflavone against HeLa cancer cells. (PubMed, Heliyon)
Notably, p21, p27, EGFR, SMAD4, JNK, ATF2, and c-JUN merged as pivotal targets contributing to TMF's anti-cancer efficacy against HeLa cells. This study is first to delineate the potential signaling pathways and core targets of TMF in treating of HeLa cancer, paving the way for further exploration of TMF's medical potential.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • SMAD4 (SMAD family member 4) • IGFBP2 (Insulin-like growth factor binding protein 2) • XIAP (X-Linked Inhibitor Of Apoptosis) • CD40LG (CD40 ligand) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKBIA (NFKB Inhibitor Alpha 2) • STAT2 (Signal transducer and activator of transcription 2) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • TNFRSF10D (TNF Receptor Superfamily Member 10d) • ATF2 (Activating Transcription Factor 2) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1) • SMAD2 (SMAD Family Member 2)
|
FASN-L
9ms
Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment. (PubMed, Cancers (Basel))
The current treatment is based on immunosuppressive therapies, which frequently produce unsatisfactory long-term responses, and for this reason, personalized approaches and targeted therapies are needed. Here, we discuss molecular pathogenesis, clinical presentation, associated autoimmune disorders, and the available treatment options, including emerging therapies.
Review • Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 mutation • FASN-L • STAT5A mutation
10ms
A randomized control trial for evaluation of transfusion related immuno-modulation in patients with meningioma. (PubMed, Transfus Apher Sci)
In conclusion, leukoreduction appeared to offer some immune response protection in term of reducing mechanical ventilation timings and cytokine level changes.
Journal • Immunomodulating
|
IL10 (Interleukin 10)
|
FASN-L • IL10 elevation
11ms
The crosstalk of CD8+ T cells and ferroptosis in cancer. (PubMed, Front Immunol)
Together, these factors build a complex network of CD8+ T cells and ferroptosis in cancer. Therefore, we aim to integrate relevant studies to reveal the potential mechanisms of crosstalk between CD8+ T cells and ferroptosis, and to summarize preclinical models in cancer therapy to find new therapeutic strategies in this review.
Review • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IRF8 (Interferon Regulatory Factor 8) • IRF1 (Interferon Regulatory Factor 1)
|
IRF1 expression • FASN-L
1year
Combined thermal ablation and liposomal granulocyte-macrophage colony stimulation factor increases immune cell trafficking in a small animal tumor model. (PubMed, PLoS One)
Systemic liposomal GM-CSF combined with RFA improves intratumoral immune cell trafficking, specifically populations initiating (DC, M1) and executing (CTL, FasL+) anti-tumor immunity. Moreover, liposomes influence synchronous untreated metastases increasing Th1, CTL and DCs infiltration.
Preclinical • Journal • Immune cell
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FASLG (Fas ligand) • CSF2 (Colony stimulating factor 2) • FOXP3 (Forkhead Box P3)
|
FASN-L
over1year
TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. (PubMed, Cancer Lett)
Vibostolimab also increased T cell chemotaxis induced by activated NK cells in vitro and in vivo. Overall, blocking TIGIT/CD155 signaling enhances the antitumor effect of expanded NK cells against CRPC; this finding supports the translational application of TIGIT mAb and NK cell combination strategies from bench to bedside for CRPC treatment.
Journal • Checkpoint inhibition • IO biomarker • Checkpoint block
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • FASLG (Fas ligand) • LAMP1 (Lysosomal Associated Membrane Protein 1) • PVR (PVR Cell Adhesion Molecule)
|
IFNG expression • FASN-L
|
vibostolimab (MK-7684)
over1year
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • SOCS1 (Suppressor Of Cytokine Signaling 1) • SOCS3 (Suppressor Of Cytokine Signaling 3)
|
FASN-L
|
decitabine
over1year
The expression of corticotropin-releasing hormone family peptides in premalignant and malignant vulvar lesions. (PubMed, Clin Transl Oncol)
Stress response system and CRH family peptides seem to have a role in inflammation maintenance and progression of vulvar premalignant lesions to malignancy. It seems that stress peptides may locally modulate the stroma through Fas/FasL upregulation, possibly contributing to vulvar cancer development.
Journal
|
FASLG (Fas ligand) • UCN (Urocortin)
|
FASN-L
over1year
Effect of Zebularine on Apoptotic Pathways in Hepatocellular Carcinoma Cell Lines. (PubMed, Int J Prev Med)
Maximal and minimal apoptosis was seen in HCCLM3 and MHCC97L cell lines, respectively. Our findings indicated that DNMTI zebularine can induce apoptosis and inhibit cell growth through both pathways (extrinsic and intrinsic) in HCC cell lines HCCLM3, MHCC97H, and MHCC97L.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
FASN-L
over1year
Prognostic and clinicopathological significance of fatty acid synthase in breast cancer: A systematic review and meta-analysis. (PubMed, Front Oncol)
No significant associations were observed between FASN expression and histological grade (OR, 0.92; 95% CI, 0.41-2.04; P=0.832), Tumor Node Metastasis (TNM) stage (OR, 1.11; 95% CI, 0.49-2.53; P=0.795), nodal metastasis (OR, 1.42; 95% CI, 0.84-2.38; P=0.183), Ki-67 labelling index (OR, 0.64; 95% CI, 0.15-2.63; P=0.533), estrogen receptor (ER) status (OR, 0.90; 95% CI, 0.61-1.32; P=0.586), or progesterone receptor (PR) status (OR, 0.67; 95% CI, 0.29-1.56; P=0.354). FASN is associated with HER2 expression and may contribute to tumor growth, but it has no significant impact on the overall prognosis of breast cancer.
Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • FASN (Fatty acid synthase)
|
HER-2 expression • EGFR positive • FASN-L • FASN overexpression
almost2years
N17350 is an emerging therapeutic modality that selectively kills cancer cells and stimulates anti-tumor immunity (AACR 2023)
Effects on primary and metastatic tumor growth, immunology, and survival were assessed in comparison to SoC agents (oxaliplatin, cyclophosphamide) or in combination with a checkpoint inhibitor (anti-CTLA4). N17350 killed and induced ICD markers in all cancer cell types tested without harming non-cancer cells, while SoC agents were similarly toxic to both cell types. Taken together, our data suggest that N17350 selectively kills cancer cells, produces complete responses in a subset of mice, induces favorable innate and adaptive immunology, and combines with checkpoint inhibitors in cold and hot tumors. Its ability to escape resistance, produce abscopal effects, and outperform SoC chemotherapies warrants further studies of this unique therapeutic modality in a clinical setting.
IO biomarker
|
CD8 (cluster of differentiation 8) • FAS (Fas cell surface death receptor)
|
FASN-L
|
cyclophosphamide • oxaliplatin • N17350
almost2years
Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line. (PubMed, Cell Mol Biol (Noisy-le-grand))
Also, it increased the expression of DR4, DR5, FAS, FAS-L, TRAIL, BAX, BAK, and APAF1 genes. In general, valproic acid seems to play its apoptotic role through intrinsic and extrinsic pathways in liver cancer.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • APAF1 (Apoptotic peptidase activating factor 1)
|
BCL2 expression • BAX expression • FASN-L
almost2years
Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab? (PubMed, Cancers (Basel))
The possibility of targeting the microenvironment is an intriguing perspective in terms of therapeutic drug development. In this review, we summarized available evidence related to the glioma microenvironment, focusing on differences within different glioma subtypes and on possible therapeutic development.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2)
|
IDH wild-type • FASN-L
almost2years
Hsp70, in Combination with IL-15 and PD-1 Blocker, Interferes with The Induction of Cytotoxic NK Cells in Relapsed Acute Myeloid Leukemia Patients. (PubMed, Cell J)
We suggested the combination of IL-15 and PD-1 blocker could enhance the killing potential of AMLNK cells. Moreover, Hsp70 in combination with IL-15 and PD-1 blocker interferes activation of AML-NK cells through unknown mechanisms.
Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • IL15 (Interleukin 15) • PRF1 (Perforin 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
|
PD-1 expression • IFNG expression • FASN-L
almost2years
CAR-NK 19-DERIVED EXTRACELLULAR VESICLES EXPRESS THE CAR AND HAVE A STRONG GRANZYME/PERFORIN MEDIATED ANTILEUKEMIC EFFECT (EBMT 2023)
All together these data demonstrated that CAR-NK EVs have a strong potential as new immune-therapeutic agents, given their low toxicity, scarce immunogenicity, associated with a high functional potential. Their use could be envisaged alone or in combination with the parental cells in order to reinforce their effect.
IO biomarker
|
CD19 (CD19 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • GZMB (Granzyme B) • IL15 (Interleukin 15) • IL1B (Interleukin 1, beta) • CD96 (CD96 Molecule) • NKG2D (killer cell lectin like receptor K1)
|
CD19 expression • NCAM1 expression • FASN-L
almost2years
Carvacrol instigates intrinsic and extrinsic apoptosis with abrogation of cell cycle progression in cervical cancer cells: Inhibition of Hedgehog/GLI signaling cascade. (PubMed, Front Chem)
Moreover, CAR inhibited the HH/GLI signaling pathway by down regulating the expression of SMO, PTCH and GLI1 proteins in cervical carcinoma cells. With evidence of the above results, our data revealed that CAR treatment suppressed the growth of HPVC33A cervical cancer cells and further elucidated the mechanistic insights into the functioning of CAR.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • SMO (Smoothened Frizzled Class Receptor) • GLI1 (GLI Family Zinc Finger 1) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • CCND1 expression • BAX expression • FASN-L • CDKN1B expression
2years
Relationship between Neuroglial Apoptosis and Neuroinflammation in the Epileptic Focus of the Brain and in the Blood of Patients with Drug-Resistant Epilepsy. (PubMed, Int J Mol Sci)
Thus, a comprehensive analysis of revealed changes in the blood and brain in DRE patients showed the neuroinflammation in the epileptic focus, which was combined with the development of apoptosis of glial cells and neurons. This creates conditions for the development of drug resistance and the epilepsy progression.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL7 (Interleukin 7)
|
FASN-L
over2years
The effect of valproic acid on intrinsic, extrinsic, and JAK/STAT pathways in neuroblastoma and glioblastoma cell lines. (PubMed, Res Pharm Sci)
Additionally, it significantly up-regulated the expression level of Bak, Bax, and Bim genes and down-regulated the expression level of Bcl-xL, Bcl-2, and Mcl-1 genes in both neuroblastoma and glioblastoma cell lines. VPA induced cell apoptosis through extrinsic, intrinsic, and JAK/STAT pathways.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein)
|
BCL2 expression • MCL1 expression • BAX expression • FASN-L
over2years
The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. (PubMed, Front Oncol)
More importantly, the small molecule inhibitor of FASN, TVB-2640, significantly inhibits lipogenic phenotype and attenuates self-renewal ability, chemotherapy resistance and USP13-mediated tumorigenesis in SCLC. Thus, our study highlights a critical role of the USP13-FASN-lipogenesis axis in SCLC cancer stemness maintenance and tumor growth, and reveals a potential combination therapy for SCLC patients.
Journal
|
FASN (Fatty acid synthase) • USP13 (Ubiquitin Specific Peptidase 13)
|
FASN-L
|
denifanstat (TVB-2640)
over2years
The Role of Decoy Receptor DcR3 in Gastrointestinal Malignancy. (PubMed, Cancer Diagn Progn)
We also present a detailed description of the pathophysiological basis that may underlie the involvement of DcR3 in gastrointestinal carcinogenesis. Based on these data, we comment on the potential applicability of DcR3 monitoring in the diagnosis and, most importantly, the prognostic stratification of patients.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
FASN-L
over2years
Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma. (PubMed, PLoS One)
The immunohistochemical evaluation of tumour sections showed fewer FAS-L-positive inflammatory cells in the IMC group. These results suggest the important contribution of CD8+ T-cells, macrophages and FAS-L in the aggressiveness of IMC.
Journal
|
CD8 (cluster of differentiation 8) • CD14 (CD14 Molecule) • GZMB (Granzyme B)
|
FASN-L
over2years
Mechanisms of GZ17-6.02 resistance. (PubMed, Anticancer Drugs)
Our findings demonstrate that GZ17-6.02 has the potential to be developed as a colon cancer therapeutic and that resistance to the drug can be partially reversed by HDAC inhibitors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FAS (Fas cell surface death receptor)
|
HER-2 expression • FASN-L
|
5-fluorouracil • GZ17-6.02
over2years
Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer. (PubMed, Front Immunol)
Dasatinib and temsirolimus are potential FASN-targeting drugs. Our model efficiently predicted prognosis in BC. FASN is central to fatty acid metabolism, and a potential indicator and regulator of ICI treatment.
Journal • IO biomarker
|
FASN (Fatty acid synthase) • MIR27A (MicroRNA 27a)
|
FASN-L
|
dasatinib • Torisel (temsirolimus)
almost3years
Large granular lymphocytic leukemia: a brief review. (PubMed, Am J Blood Res)
The advances in the knowledge of molecular pathways associated with the disease have brought few targeted therapies into the limelight. We discuss here the evolution, epidemiology, demographic profile, pathophysiology, differential diagnosis, the available treatment options along with the survival and prognostic variables which may help us in better understanding and better management of the disease and hopefully, paving the way for a targeted clinical approach.
Review • Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1)
|
FASN-L
almost3years
GZ17-6.02 and axitinib interact to kill renal carcinoma cells. (PubMed, Oncotarget)
We conclude that GZ17-6.02 and axitinib interact to kill requiring ER stress signaling, autophagy and death receptor signaling. Autophagic degradation of HDACs played a key role in enhancing MHCA expression and of a potential improved response to checkpoint inhibitory immunotherapy.
Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • FADD (Fas associated via death domain) • FAS (Fas cell surface death receptor) • ATG5 (Autophagy Related 5) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • BAK1 (BCL2 Antagonist/Killer 1) • BECN1 (Beclin 1)
|
MCL1 expression • FASN-L
|
Inlyta (axitinib) • GZ17-6.02
almost3years
Her-2 directed systemic delivery of fatty acid synthase (FASN) siRNA with novel liposomal carrier systems in the breast cancer mouse model. (PubMed, J Drug Target)
The gene silencing effects of targeted FASN-liposomes were found significantly superior, resulting in 30%-40% downregulation in FASN as compared to non-targeted similar formulations. Both types of FASN immunoliposomes provided a highly efficient approach for targeted delivery in Her-2-expressed breast cancer and thus offered a promising anticancer strategy in the clinical therapy.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • FASN (Fatty acid synthase) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
HER-2 overexpression • FASN-L
almost3years
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. (PubMed, Oncotarget)
The drugs also increased the phosphorylation of the AMPK and ATG13, effects blocked by knock down of ATM. Knock down of ATM or the AMPK, or expression of activated mTOR significantly reduced the abilities of GZ17-6.02 and palbociclib to enhance autophagosome formation and autophagic flux.
Journal
|
ER (Estrogen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • FAS (Fas cell surface death receptor) • ATG5 (Autophagy Related 5) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • BECN1 (Beclin 1)
|
ER positive • MCL1 expression • BAX expression • ATM expression • FASN-L • AMPK expression
|
Ibrance (palbociclib) • 5-fluorouracil • GZ17-6.02
3years
Antitumor activity and immunomodulation mechanism of a novel polysaccharide extracted from Polygala tenuifolia Willd. evaluated by S180 cells and S180 tumor-bearing mice. (PubMed, Int J Biol Macromol)
Additionally, the PTP revised the immune organ indexes, the activities of NK cells and lymphocytes, and induced the secretion of IL-2 (7.34-16.17%), IFN-γ (14.34-20.85%) and TNF-α (12.32-22.58%) in vivo. Thus, PTP can induce cell apoptosis and activate the immunoregulation mechanism thereby exhibiting biological activity.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9)
|
FASN-L
3years
Journal • IO biomarker
|
CD19 (CD19 Molecule) • IL2 (Interleukin 2)
|
FASN-L
|
zoledronic acid
3years
Effect of Zebularine in Comparison to Trichostatin A on the Intrinsic and Extrinsic Apoptotic Pathway, Cell Viability, and Apoptosis in Hepatocellular Carcinoma SK-Hep 1, Human Colorectal Cancer SW620, and Human Pancreatic Cancer PaCa-44 Cell Lines. (PubMed, Iran J Pharm Res)
The result indicated that zebularine and TSA changed the expression level of the Bax, Bak, Bim Bcl-2, Bcl-xL, Mcl-1, DR4, DR5, FAS, FAS-L, TRAIL, DNA methyltransferase 1, 3a, and 3b, histone deacetylase inhibitors 1, 2, and 3 by which induced cell apoptosis and inhibit cell growth in all three cell lines. Concluding, TSA induced its role through both extrinsic and intrinsic apoptotic pathways in three cell lines, whereas, zebularine played its role via both pathways in the SK-Hep 1cell line, it had no significant effect on Bcl-2, Bcl-xL, and Mcl-1 gene expression in SW620 and PaCa-44 cell lines.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • DNMT1 (DNA methyltransferase 1)
|
BCL2 expression • MCL1 expression • BAX expression • FASN-L
3years
Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival. (PubMed, Cancers (Basel))
In addition, a strong association between tumor-infiltrating CD4+ cells and the presence of CD44s expression in tumor samples was observed. Analysis of TIL and tumor markers related to tumor biology could be useful to stratify patients and monitor the response to therapy, as well as to assist with the development of immunotherapy strategies to improve the effects of cytotoxic TIL to eradicate the tumor cells.
Clinical • Journal • Tumor-Infiltrating Lymphocyte • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD44 (CD44 Molecule) • FAS (Fas cell surface death receptor)
|
CD44 expression • FASN-L
3years
Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors. (PubMed, Acta Cardiol)
Evaluation of polymorphisms genes of p53 (rs1042522), NOS3 (rs1799983), GPX1 (rs1050450), and NADPH oxidase (rs4673) can be recommended before CT for the risk assessment of AIC development. The serum levels of NT-proBNP and soluble Fas-L after CT may be considered as non-invasive biomarkers for prediction of AIC development during the 12 months.
Clinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CASP8 (Caspase 8) • FAS (Fas cell surface death receptor) • IL1B (Interleukin 1, beta) • NOS3 (Nitric oxide synthase 3) • SOD2 (Superoxide Dismutase 2)
|
FASN-L
3years
Swertia chirayita suppresses the growth of non-small cell lung cancer A549 cells and concomitantly induces apoptosis via downregulation of JAK1/STAT3 pathway. (PubMed, Saudi J Biol Sci)
Treatment of Sw-EtOH modulates the expression level of various STAT3 associated proteins, including Bcl-XL, Bcl-2, Mcl-1, Bax, p53, Fas, Fas-L, cyclinD1, c-myc, IL-6, p21 and p27 in NSCLC cells. Thus, our study provided a strong impetus that Sw-EtOH holds the translational potential of being further evaluated as efficient cancer therapeutics and a preventive agent for the management of NSCLC.
Journal • PARP Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • JAK1 (Janus Kinase 1) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression • FASN-L
3years
ARID1A Controls a Novel Transcriptional Network Regulating FAS in Follicular Lymphoma (ASH 2021)
Both approaches showed significantly reduced FAS expression in ARID1A mutant FL ( P <0.05 for GEP, P <0.0001 for QMI; Fig E ). In summary, we show that ARID1A loss is directly linked to reduced FAS expression via a novel RUNX3/ETS1 transcriptional network, potentially opening avenues for therapeutic targeting of this clinically relevant perturbation.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • ETS1 (ETS Proto-Oncogene 1) • RUNX3 (RUNX Family Transcription Factor 3)
|
ARID1A mutation • FASN-L
3years
Effects of trichostatin A on the intrinsic and extrinsic apoptotic pathway, cell viability, and apoptosis induction in hepatocellular carcinoma cell lines. (PubMed, Gastroenterol Hepatol Bed Bench)
Maximal and minimal apoptosis was seen in the MHCC97H and HCCLM3 cell lines (93.94% and 39.68%, respectively) after 24 and 48 h. Therefore, the MHCC97H cell line was more sensitive to TSA. The current findings demonstrated that the HDAC inhibitor TSA can induce apoptosis and inhibit cell growth through both mitochondrial/intrinsic and cytoplasmic/extrinsic apoptotic pathways in hepatocellular carcinoma HCCLM3, MHCC97H, and MHCC97L cell lines.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • HDAC1 (Histone Deacetylase 1)
|
FASN-L
over3years
TRIB3 regulates FSHR expression in human granulosa cells under high levels of free fatty acids. (PubMed, Reprod Biol Endocrinol)
During exposure to a high FFA content, TRIB3 can reduce FSHR expression through stimulation of the Akt/GSK3β pathway in human GCs. This response may contribute to inducing oocyte maturation.
Journal
|
ATF4 (Activating Transcription Factor 4) • TRIB3 (Tribbles Pseudokinase 3)
|
FASN-L
over3years
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. (PubMed, Pigment Cell Melanoma Res)
Combined knock down of Beclin1 and CD95 abolished cell death. Our data demonstrate that PDX melanoma cells expressing B-RAF V600E are susceptible to being killed by neratinib and more so when combined with HDACi.
Journal
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • FAS (Fas cell surface death receptor) • ATG5 (Autophagy Related 5) • BECN1 (Beclin 1)
|
BRAF V600E • BRAF V600 • EGFR expression • MCL1 expression • ATG5 overexpression • FASN-L • ATG5 expression
|
Nerlynx (neratinib)
over3years
MiR-448-5p/VEGFA Axis Protects Cardiomyocytes from Hypoxia Through Regulating the FAS/FAS-L Signaling Pathway. (PubMed, Int Heart J)
In addition, miR-448-5p mimic inhibited the effect of hypoxia on promoting the expressions of FAS and FAS-L of H9C2 cells. Inhibitors had the opposite effect on cell hypoxia model.The miR-448-5p/VEGFA axis could protect cardiomyocytes from hypoxia through inhibiting the FAS/FAS-L signaling pathway.
Journal • IO biomarker
|
CASP3 (Caspase 3)
|
BCL2 expression • BAX expression • VEGFA expression • FASN-L
over3years
Apoptotic mechanisms of gastric cancer cells induced by isolated erinacine S through epigenetic histone H3 methylation of FasL and TRAIL. (PubMed, Food Funct)
Moreover, our data revealed that activation of the ROS-derived and AKT/FAK/PAK1 pathways is involved in the erinacine S-mediated transcriptional activation of Fas-L and TRAIL through H3K4 trimethylation on their promoters. Together, this study sheds light on the anticancer effects of erinacine S on gastric cancer and its molecular mechanism in vitro and in vivo.
Journal • IO biomarker • Epigenetic controller
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • FASLG (Fas ligand) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • FASN-L
over3years
Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma. (PubMed, Biomed Res Int)
BP/LPPC exhibited higher cell uptake and cytotoxicity than BP alone, and combined with clinical drug etoposide (VP-16), BP/LPPC showed a synergistic effect against HCC cells...In conclusion, the LPPC complex improved the antitumor activity of BP in terms of cytotoxicity, cell cycle regulation and cell apoptosis, and BP/LPPC synergistically inhibited cell growth during combination treatment with VP-16 in HCC cells. Therefore, BP/LPPC is potentially a good candidate for clinical drug development or for use as an adjuvant for clinical drugs as a combination therapy for hepatocellular carcinoma.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
FASN-L
|
etoposide IV
over3years
Cell death pathways and viruses: Role of microRNAs. (PubMed, Mol Ther Nucleic Acids)
The present review summarizes the existing knowledge on virus-regulated miRNAs involved in the modulation of cell death pathways. Understanding the mechanisms for virus-mediated regulation of cell death pathways could provide valuable information to improve the diagnosis and treatment of many viral diseases.
Review • Journal
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR192 (MicroRNA 192)
|
FASN-L